{
    "2021-02-01": [
        [
            {
                "time": "",
                "orginal_text": "2021年医药行业如何投资？高瓴A股医药公司持仓曝光",
                "features": {
                    "keywords": [
                        "高瓴",
                        "A股",
                        "医药",
                        "持仓"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "泰格医药(03347.HK)：2020年A股员工持股计划完成非交易过户",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "员工持股",
                        "非交易过户"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "泰格医药(300347.SZ)：2020年A股员工持股计划完成非交易过户",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "员工持股",
                        "非交易过户"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "抱团股爆发，沪指重上3500！创业板次新股最猛飙100%",
                "features": {
                    "keywords": [
                        "抱团股",
                        "沪指",
                        "创业板",
                        "次新股"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "高瓴资本概念股普遍活跃，泰格医药、国瓷材料、甘李药业、恩捷股份大涨",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "泰格医药",
                        "国瓷材料",
                        "甘李药业",
                        "恩捷股份"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "材料"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "【异动股】泰格医药(03347-HK)涨5.51%",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "异动股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "中金指泰格医药(03347-HK)海外业务有较强增长力首予目标价200港元",
                "features": {
                    "keywords": [
                        "中金",
                        "泰格医药",
                        "海外业务",
                        "目标价"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "中泰证券--泰格医药：主业加速恢复，全球布局有望逐步推进【公司研究】",
                "features": {
                    "keywords": [
                        "中泰证券",
                        "泰格医药",
                        "主业恢复",
                        "全球布局"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "医药生物行业报告简版：药品集采常态化推进 看好创新主线、API+制剂一体化龙头企业",
                "features": {
                    "keywords": [
                        "医药生物",
                        "药品集采",
                        "创新",
                        "API+制剂"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}